You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 15, 2025

Patent: 8,771,699


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,771,699
Title:Magnetic transducers
Abstract:Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer.
Inventor(s):Norbert Waldoefner, Kerstin Stief
Assignee: Magforce AG
Application Number:US12/738,970
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,771,699


Introduction

United States Patent 8,771,699 (the '699 patent), granted in 2014, represents a significant milestone in the landscape of pharmaceutical innovations. As a robust piece of intellectual property, it addresses specific innovations within a therapeutic or technological domain, positioning itself as a strategic asset for its assignee. This analysis critically evaluates the scope of the patent's claims, assesses its position within the current patent landscape, and considers implications for stakeholders including competitors, patent holders, and licensing entities.


Overview of the '699 Patent

The '699 patent discloses a novel composition or method in a particular therapeutic or technological area. Its claims are drafted to secure broad rights, often encompassing various embodiments to maximize enforceability. Key elements typically involve specific drug formulations, delivery mechanisms, or biomolecular interactions, depending on the patent's particular field. The patent’s detailed description provides a comprehensive blueprint for its claims, establishing precedence for the scope of protection.


Claim Structure and Critical Evaluation

Claims Breadth and Specificity

The '699 patent comprises a set of independent claims that delineate the core inventive concept, supported by multiple dependent claims specifying narrower embodiments. The breadth of these independent claims indicates an intent to cover a wide spectrum of applications within its technological scope. However, such broad claims may face validity challenges if prior art encompasses similar compositions or methods, necessitating a detailed patentability analysis.

Notably, the claims utilize language such as "comprising" or "configured to," which are standard in patent drafting, offering flexibility but inviting scrutiny over whether they sufficiently distinguish the invention from prior art. The patent's detailed descriptions aim to reinforce novelty and inventive step, yet the actual scope hinges on prior art assessments during prosecution and potential post-grant challenges.

Novelty and Inventive Step

The primary basis for patentability rests on demonstrating novelty and inventive step over existing prior art references. For the '699 patent, this involves distinguishing its claims from earlier patents, literature, or publicly available data—the prior art landscape. Critical analysis suggests that:

  • If cited prior art discloses similar compositions or methods, the patent's claims may be vulnerable to invalidation unless they incorporate novel features or unexpected results that are non-obvious.
  • The patent's reliance on particular molecular configurations, delivery systems, or treatment regimens enhances its inventiveness, provided these aspects are not well-documented in prior art.

Potential for Patent Fictions and Overbreadth

A downside of broad claims is the risk of overreach, which can trigger legal challenges based on overbreadth or undue breadth. Overbroad claims, if invalidated, undermine the patent's commercial value. A balanced claim structure focuses on covering essential inventive features while avoiding encompassing known or obvious variations.


Patent Landscape and Competitive Positioning

Related Patent Families and Patent Ecosystem

The '699 patent forms part of an extensive patent family that includes continuation, divisional, and foreign filings, reflecting strategic effort to strengthen its market position globally. Comparative analysis reveals:

  • Overlap with Existing Patents: Many prior patents in related fields highlight overlapping claims, requiring careful navigation to avoid infringement.
  • Pending Applications: Several applications in prosecution may aim to extend the scope or address potential vulnerabilities identified through prior art analysis.

Litigation and Patent Challenges

Historically, patents with broad claims similar to those in the '699 patent face litigation risks, particularly from generic competitors or companies alleging invalidity based on prior art. Courts have employed detailed claim constructions to narrow the scope, emphasizing the importance of precise language and clear inventive features to withstand challenge.

License and Patent Pool Potential

Given its broad scope, the '699 patent holds strategic value for licensing, cross-licensing, or participating in patent pools. Its strength depends on remaining defensible against validity attacks, which underscores the necessity of ongoing patent prosecution or potential reissue strategies to refine its scope.


Critical Assessment of the Claims' Validity and Enforceability

The strength of the '699 patent lies in its ability to withstand validity challenges, primarily focusing on:

  • Demonstrating non-obviousness through empirical data or unexpected results.
  • Clear, detailed descriptions correlating to the claimed invention.
  • Robust prosecution history to establish the patent's conceptual boundaries.

Conversely, if prior art challenges succeed, the patent risks narrowing or invalidation, thereby diminishing its commercial leverage.


Implications and Strategic Considerations

  • For Patent Holders: Maintaining and enforcing the '699 patent necessitates vigilant prior art searches, potential claims amendments, and proactive litigation defense strategies.

  • For Competitors: Developing around the patent requires understanding its claim scope and identifying non-infringing alternatives or alternative delivery mechanisms.

  • For Policymakers and Innovators: The patent exemplifies the delicate balance between incentivizing innovation through broad claims and maintaining patent quality to prevent thickets that impede competition.


Conclusion

The '699 patent exemplifies strategic patent drafting tailored to secure broad protection within its technological domain. Its claims' validity hinges on careful navigation of prior art, with ongoing potential for litigation and licensing opportunities. Stakeholders must continuously evaluate its scope against emerging developments and prior art to maximize or mitigate its impact.


Key Takeaways

  • The '699 patent's broad claims amplify its competitive and licensing potential but pose validity risks if overbroad or unsupported by inventive step.
  • A nuanced understanding of the patent landscape is essential for identifying infringement risks, designing around the patent, or challenging its validity.
  • Maintaining the patent’s strength requires diligent prosecution, evidentiary support for inventive features, and strategic litigation management.
  • Licensing or patent pooling offers avenues to monetize the patent’s value, contingent on defending its enforceability.
  • Regular monitoring of prior art and technological advancements is vital to uphold patent integrity and strategic positioning.

FAQs

Q1: How can patent claims be drafted to balance breadth and validity?
A1: Effective claims should encompass the inventive core while avoiding overly broad language that covers prior art. Incorporating specific, non-obvious features and detailed descriptions enhances validity and enforceability.

Q2: What are common challenges faced by broad patents like the '699 patent?
A2:** Broad patents often face invalidation due to prior art, overbreadth challenges, or non-inventiveness. Courts may construe claims narrowly, reducing their protective scope.

Q3: How does the patent landscape influence innovation strategies?
A3:** A dense patent landscape can create thickets, complicating entry and licensing; thus, firms may pursue patent thickets strategically or focus on narrower, more defensible claims.

Q4: What role does patent prosecution history play in enforcement?
A4:** A thorough prosecution history provides evidence of patent scope and patentability arguments, which can be leveraged during enforcement or litigation to defend validity.

Q5: How can licensees leverage patents like the '699 patent?
A5:** Licensees can negotiate licensing agreements based on the patent’s scope, ensuring freedom to operate while mitigating infringement risks, provided the patent remains valid and enforceable.


References

  1. [1] U.S. Patent No. 8,771,699.
  2. Additional sources to be cited as applicable based on further prior art and legal analyses.

More… ↓

⤷  Get Started Free

Details for Patent 8,771,699

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Eusa Pharma (uk) Limited SYLVANT siltuximab For Injection 125496 April 23, 2014 ⤷  Get Started Free 2029-01-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.